The primary study objectives are: to evaluate (1) the change in ocular discomfort at 30 days and (2) the change in signs and symptoms of ocular surface disease in demodex-positive subjects beginning the use of Avenova.
This is a prospective study of subjects who have been diagnosed with bilateral demodex blepharitis. Qualified symptomatic eyes will be randomized and monitored for 30 days; one eye will undergo Avenova treatment twice daily and one eye will not undergo any study treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
14
Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.
Minnesota eye Consultants, PA
Bloomington, Minnesota, United States
Change in Severity of Markers of Inflammation
Clinical parameters include prevalence of demodex mites.
Time frame: 30 days
Change in Severity of Markers of Inflammation
Clinical exam parameters include prevalence of tear film break up time.
Time frame: 30 days
Change in Severity of Markers of Inflammation
Clinical exam parameters include corneal and conjunctival staining.
Time frame: 30 days
Change in Severity of Markers of Inflammation
Clinical parameters include evaluation of meibomian gland including evaluation of lipid layer thickness..
Time frame: 30 days
Change in Severity of Markers of Inflammation using tear osmolarity.
Clinical parameters include tear osmolarity.
Time frame: 30 days
Change in Severity of Markers of Inflammation
Clinical parameters include tear ferning patterns.
Time frame: 30 days
Change in Severity of Markers of Inflammation
Clinical parameters include meibomian gland evaluation
Time frame: 30 days
Change in Ocular Discomfort
Change in ocular discomfort based on scores from Eyelid Inflammation questionnaire.
Time frame: 30 days
Change in Ocular Discomfort
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in ocular discomfort based on scores from Ocular Surface Disease Index questionnaire. Scored on a scale of 0-100, with higher scores indicating greater disability.
Time frame: 30 days